BR112022011834A2 - Derivado de pirimidina e uso do mesmo - Google Patents
Derivado de pirimidina e uso do mesmoInfo
- Publication number
- BR112022011834A2 BR112022011834A2 BR112022011834A BR112022011834A BR112022011834A2 BR 112022011834 A2 BR112022011834 A2 BR 112022011834A2 BR 112022011834 A BR112022011834 A BR 112022011834A BR 112022011834 A BR112022011834 A BR 112022011834A BR 112022011834 A2 BR112022011834 A2 BR 112022011834A2
- Authority
- BR
- Brazil
- Prior art keywords
- pyrimidine derivative
- inhibitory activity
- disease
- mlk3
- tuberculosis
- Prior art date
Links
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical class C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 title abstract 2
- 230000002401 inhibitory effect Effects 0.000 abstract 2
- 150000003230 pyrimidines Chemical class 0.000 abstract 2
- 101001005602 Homo sapiens Mitogen-activated protein kinase kinase kinase 11 Proteins 0.000 abstract 1
- 108010020246 Leucine-Rich Repeat Serine-Threonine Protein Kinase-2 Proteins 0.000 abstract 1
- 102100032693 Leucine-rich repeat serine/threonine-protein kinase 2 Human genes 0.000 abstract 1
- 102100025207 Mitogen-activated protein kinase kinase kinase 11 Human genes 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 208000018737 Parkinson disease Diseases 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 208000015181 infectious disease Diseases 0.000 abstract 1
- 230000002458 infectious effect Effects 0.000 abstract 1
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 201000008827 tuberculosis Diseases 0.000 abstract 1
- 230000003612 virological effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/06—Antibacterial agents for tuberculosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/48—Two nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
- C07F9/65583—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
- C07F9/65586—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system at least one of the hetero rings does not contain nitrogen as ring hetero atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Psychology (AREA)
- Gastroenterology & Hepatology (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
DERIVADO DE PIRIMIDINA E USO DO MESMO. A presente invenção refere-se a um derivado de pirimidina e uso do mesmo. O derivado de pirimidina tem excelente atividade inibidora de MLK3 e atividade inibidora de LRRK2 e, portanto, pode ser usado em uma composição farmacêutica para prevenir ou tratar cânceres, doenças infecciosas por vírus, doença de Parkinson, esteatose hepática não alcoólica e tuberculose.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR20190168363 | 2019-12-16 | ||
PCT/KR2020/018478 WO2021125803A1 (ko) | 2019-12-16 | 2020-12-16 | 신규한 피리미딘 유도체 및 이의 용도 |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112022011834A2 true BR112022011834A2 (pt) | 2022-08-30 |
Family
ID=76607384
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112022011834A BR112022011834A2 (pt) | 2019-12-16 | 2020-12-16 | Derivado de pirimidina e uso do mesmo |
Country Status (6)
Country | Link |
---|---|
EP (1) | EP4079726A4 (pt) |
JP (1) | JP2023507319A (pt) |
KR (1) | KR102572704B1 (pt) |
CN (1) | CN114829344A (pt) |
BR (1) | BR112022011834A2 (pt) |
CA (1) | CA3161667A1 (pt) |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7122679B2 (en) | 2000-05-09 | 2006-10-17 | Cephalon, Inc. | Multicyclic compounds and the use thereof |
GB0305929D0 (en) * | 2003-03-14 | 2003-04-23 | Novartis Ag | Organic compounds |
KR101149295B1 (ko) * | 2006-12-08 | 2012-07-05 | 아이알엠 엘엘씨 | 단백질 키나제 억제제로서의 화합물 |
AU2008296479A1 (en) * | 2007-08-28 | 2009-03-12 | Dana Farber Cancer Institute | Amino substituted pyrimidine, pyrollopyridine and pyrazolopyrimidine derivatives useful as kinase inhibitors and in treating proliferative disorders and diseases associated with angiogenesis |
LT2300013T (lt) * | 2008-05-21 | 2017-12-27 | Ariad Pharmaceuticals, Inc. | Fosforo dariniai kaip kinazių inhibitoriai |
EA024729B1 (ru) * | 2009-11-13 | 2016-10-31 | Джиноско | Киназные ингибиторы |
WO2015158310A1 (zh) * | 2014-04-18 | 2015-10-22 | 山东轩竹医药科技有限公司 | 一种酪氨酸激酶抑制剂及其用途 |
CN106459007B (zh) * | 2014-06-17 | 2020-02-28 | 韩国化学研究院 | 嘧啶-2,4-二胺衍生物及包含其作为有效成分的抗癌用药学组合物 |
WO2016007540A2 (en) * | 2014-07-10 | 2016-01-14 | The J. David Gladstone Institutes | Compositions and methods for treating dengue virus infection |
CN105524045B (zh) * | 2014-10-22 | 2020-04-10 | 山东轩竹医药科技有限公司 | 四环类间变性淋巴瘤激酶抑制剂 |
CN106146525B (zh) * | 2015-04-10 | 2018-11-02 | 山东轩竹医药科技有限公司 | 三并环类间变性淋巴瘤激酶抑制剂 |
WO2016167511A2 (ko) * | 2015-04-14 | 2016-10-20 | 한국화학연구원 | N2-(2-메톡시페닐)피리미딘 유도체, 이의 제조 방법 및 이를 유효 성분으로 함유하는 암의 예방 또는 치료용 약학적 조성물 |
KR101876514B1 (ko) | 2016-11-08 | 2018-07-10 | 한국화학연구원 | 신규한 피리미딘화합물, 이의 제조방법 및 이를 유효성분으로 함유하는 암 및 염증질환의 예방 또는 치료용 약학적 조성물 |
JP7025426B2 (ja) * | 2016-11-30 | 2022-02-24 | アリアド ファーマシューティカルズ, インコーポレイテッド | 造血前駆体キナーゼ1(hpk1)阻害剤としてのアニリノピリミジンas |
CN110678182B (zh) * | 2017-02-24 | 2022-08-23 | 大邱庆北尖端医疗产业振兴财团 | 含有能够穿透血脑屏障的化合物作为预防或治疗脑癌的有效成分的药物组合物 |
-
2020
- 2020-12-16 EP EP20901025.5A patent/EP4079726A4/en active Pending
- 2020-12-16 CA CA3161667A patent/CA3161667A1/en active Pending
- 2020-12-16 KR KR1020200176636A patent/KR102572704B1/ko active IP Right Grant
- 2020-12-16 BR BR112022011834A patent/BR112022011834A2/pt unknown
- 2020-12-16 CN CN202080087166.5A patent/CN114829344A/zh active Pending
- 2020-12-16 JP JP2022536712A patent/JP2023507319A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
CA3161667A1 (en) | 2021-06-24 |
EP4079726A1 (en) | 2022-10-26 |
EP4079726A4 (en) | 2024-01-24 |
CN114829344A (zh) | 2022-07-29 |
KR20210076879A (ko) | 2021-06-24 |
KR102572704B1 (ko) | 2023-08-30 |
JP2023507319A (ja) | 2023-02-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112022010349A2 (pt) | Compostos bifuncionais para degradar btk por meio de via da ubiquitina-proteossoma | |
BR112018004175A2 (pt) | novo composto pirazolo[3,4-d]pirimidina ou sal deste | |
CL2018001089A1 (es) | Sales de valbenazina y polimorfos de las mismas. | |
WO2016196776A3 (en) | Inhibitors of bruton's tyrosine kinase | |
DOP2014000260A (es) | Compuestos d-aminoácidos para enfermedad hepática | |
ECSP088350A (es) | Pirazolopirimidinas como inhibidores de protein quinasas | |
BR112015011171A2 (pt) | compostos de pirrolopirimidina como inibidores da quinase | |
BR112016008016A2 (pt) | inibidores de kras g12c | |
WO2018115097A9 (en) | Ophthalmic composition for treatment of dry eye disease | |
BR112017024928A2 (pt) | Métodos para prevenção da diabetes ou pré- diabetes em um indivíduo, para melhoria da resposta à glicose em um indivíduo com intolerância à glicose, para manutenção da resposta à glicose em um indivíduo com tolerância à glicose e para melhoria da saúde de um indivíduo, composição probiótica e composição farmacêutica | |
DOP2010000304A (es) | Composiciones y metodos de preparacion y uso de las mismas | |
BR112019001923A2 (pt) | moduladores de nmda de espiro-lactama e métodos de sua utilização | |
BR112014018728A8 (pt) | Compostos de purinonas como inibidores de quinase | |
BRPI1011838B8 (pt) | compostos de carboxamida heterocíclica de diamino, seu uso, composição farmacêutica que os compreende e inibidor contra a atividade de cinase de proteína de fusão eml4-alk | |
CL2008002294A1 (es) | Compuestos derivados de benzotiazol acetamida y sus sales farmaceuticamente aceptables; composicion farmaceutica de dichos compuestos; su uso para tratar enfermedades mediadas por pi3 quinasa incluyendo melanoma, carcinoma y otras condiciones derivadas del cancer. | |
BR112015020118A2 (pt) | derivados de 2-aminopirimidina para o tratamento de infecções virais | |
TN2016000094A1 (en) | Inhibitors of bruton's tyrosine kinase. | |
CL2011000489A1 (es) | Compuestos derivados de pirimido[5,4-d]pirimidina, los cuales actuan como inhibidores de tirosina-quinasas; y composiciones farmaceuticas que los comprenden, utiles en el tratamiento de enfermedades que se caracterizan por una proliferacion celular excesiva o anomala | |
WO2016004305A3 (en) | Inhibitors of bruton's tyrosine kinase | |
MX2022016405A (es) | Análogos de nucleósido de 1¿-ciano y usos de estos. | |
BR112013008140A2 (pt) | "compostos imidazotriazinona". | |
CR8569A (es) | Inhibidores de integrasa de vih | |
ECSP099250A (es) | USO DE 2-6-(3-amino-piperidin-1-Il)-3-metil-2,4-dioxo-3,4-dihIdro-2H-pIrimidin-1-IlmetIL-4-fluoro-benzonitrilo | |
WO2015120237A3 (en) | 4'-difluoromethyl substituted nucleoside derivatives as inhibitors of influenza rna replication | |
BRPI0816798A2 (pt) | composto, composição farmacêutica, métodos para inibir a ação do glicogênio sintase cinase-3, e para tratar, prevenir ou melhorar uma doença, uso de um composto, e, artigo de fabricação |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B06W | Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette] |